Drug Profile
Research programme: muscarinic M2 receptor antagonists - Innoviva
Alternative Names: Overactive bladder therapeutics - Innoviva; THRX-326151Latest Information Update: 23 Nov 2016
Price :
$50
*
At a glance
- Originator Theravance
- Developer Innoviva
- Class Piperidines; Pyrrolidines; Small molecules
- Mechanism of Action Muscarinic M2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 10 Sep 2007 Preclinical trials in Overactive bladder in USA (IV)